Pfizer insiders sold $135K in the past 12 months. How much of their stake is that?

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

21 of 25 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (18 exactly, 3 with a minor or footnoted difference). For 4 we show sales but not holdings; the ! icon on their rows explains why. Percentages cover 11 of 25 officers and directors. Left out: Albert Bourla, Lidia Fonseca, Payal Sahni and Jennifer Damico (holdings couldn't be fully reconciled); Johnson Nora (most holdings were last confirmed in 2008); Shantanu Narayen, Joseph Echevarria, Dan Littman, James Quincey, Susan Hockfield, Andrew Baum and Mortimer Buckley (held no vested shares at the start); James Smith (most holdings were last confirmed in 2016); Susan Desmond-Hellmann (most holdings were last confirmed in 2020). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

Officer and director open-market sales: $135K across 5,278 shares. Plan status and stated purpose are separate questions, and a sale can have both.

Sales by month

Less than usual: less than one-twentieth of the 5-year average. 1 insider sold; the average is 3 a year.

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

All 5,131 Forms 3, 4 and 5 filed for Pfizer (SEC CIK 78003) from Jun 10, 2002 to Oct 1, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 61 filings were left out because Pfizer filed them as an owner of another company's stock. 191 older filings exist only on paper and could not be read.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology